CClinicalTrials.gg
CompletedNCT07190911COVID-SMELLUpdated Oct 2, 2025

Efficacy of Olfactive Training on Loss of Smell and Taste Caused by SARS CoV2 COVID-19 (Covid-Smell)

An interventional study of Olfactory rehabilitation consists of smelling a series of spices every day for 2 months in COVID - 19, sponsored by Centre Hospitalier Universitaire de la Guadeloupe. Completed at 1 site in Guadeloupe. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Centre Hospitalier Universitaire de la Guadeloupe · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 4 years 10 months after the study started (first participant enrolled Nov 2020, registered Sep 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate efficiency of two months of olfactive training on olfactory and taste loss secondary to covid-19. We will compare 2 groups : olfactive training group versus no olfactive training group.

Read the detailed description

The purpose of this study is to evaluate efficiency of two months of olfactive training on olfactory and taste loss secondary to covid-19. We will compare 2 groups : olfactive training group versus no olfactive training group.

02

Conditions studied

  • COVID - 19

Browse trials for

Keywords

  • Covid-19
  • olfactory training
  • olfactory and taste loss
03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's enrollment of 40 is below the median of 100 across 4,099 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Centre Hospitalier Universitaire de la Guadeloupe is the lead sponsor of 47 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • SARS-CoV-2 infection suspect or confirmed
  • supported by CHU Guadeloupe
  • with brutal olfactory or taste loss
  • affiliated or beneficiary of a social security scheme
  • informed consent signed

Exclusion criteria

Exclusion Criteria:

  • recent rhinosinusitis, less than 6 months
  • lingual pathology
  • communication disorder
  • Patients subject to a justice safeguard
  • Allergy to several spices that are part of the rehabilitation set
  • Pregnant or breastfeeding women
  • Absence of signed consent
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    olfactory training arm

    with a daily olfactory training during 2 month

    Other: Olfactory rehabilitation consists of smelling a series of spices every day for 2 months

  • No intervention
    no olfactory training

Interventions

  • OtherOlfactory rehabilitation consists of smelling a series of spices every day for 2 months

    Olfactory rehabilitation consists of smelling a series of spices every day for 2 months: vanilla, coffee, dill, thyme, cinnamon, cloves, lavender, coriander, light vinegar, mint, and cumin. This rehabilitation is based on the protocols proposed by SFORL (French ORL society) and Oleszkiewicz et al.8 Allergies to certain spices will be noted at the start of the study: * in known allergy: change by another spice which belongs to the same chemical category. * in case of allergies to several scents: patient is not included in the study. * in case of allergy appearing during participation: clinical evaluation by ENT, change by another spice which belongs to the same chemical category. * in case of allergies to several scents occuring during participation: patient is excluded from the study.

06

What researchers measure

Primary outcomes

  1. Taste and Smell Survey (TSS).

    Patients will have this auto evaluation scale at the inclusion (D0) and 2 month after inclusion (D60).

    Time frame: Baseline and 2 months

Secondary outcomes

  1. Sniffin' stick test :

    The Sniffin' Stick Test assesses the sense of smell by measuring odor detection threshold, discrimination, and identification, and is used for diagnosing and monitoring olfactory disorders.

    Time frame: 2 month

  2. Olfaction and taste evolution evaluated with a daily visual scale

    Visual analogue scale from 0 to 10 to assess dysosmia and dysgeusia, with 0 indicating normal function and 10 indicating complete deficit.

    Time frame: Every day from inclusion to 2 months

07

Study locations

1 site
  • Chu de La Guadeloupe
    Pointe-à-Pitre, 97159, Guadeloupe
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07190911
Lead sponsor
Centre Hospitalier Universitaire de la Guadeloupe
Responsible party
Sponsor
First posted
Sep 24, 2025
Start date
Nov 18, 2020
Primary completion
Mar 9, 2022
Completion
Mar 9, 2022
Last update
Oct 2, 2025

Study contacts

Suzy Duflo, MD PhD
principal investigator · CHU de la Guadeloupe

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion